10-K: VivoSim Labs Shifts Focus to 3D Tissue Testing Services

VivoSim Labs, Inc. (VIVS) has transitioned from a clinical-stage biotechnology company to a pharmaceutical and biotechnology services provider focused on 3D human tissue models for drug testing.

Summary

• VivoSim Labs, Inc. has officially changed its business model, shifting from developing drugs for inflammatory bowel disease (IBD) to providing testing services for drugs and drug candidates using 3D human tissue models of the liver and intestine.
• The company sold its FXR program in March 2025 for $10 million, receiving $9 million upfront and $1 million in escrow, with potential future milestones up to $50 million.
• In July 2026, VivoSim received a $5 million milestone payment related to the FXR program.
• The company's liver toxicology platform demonstrated a predictive power of 87.5% sensitivity and 100% specificity in identifying liver toxicity.
• VivoSim Labs reported a net loss of $13.8 million for the year ended March 31, 2026, compared to a net loss of $2.5 million for the prior year.
• The company ended its Mosaic Cell Sciences division's commercial operations in Q3 fiscal 2025.
• As of March 31, 2026, VivoSim Labs had $5.0 million in cash and cash equivalents and a working capital of $3.8 million.
• The company has substantial additional funding requirements and faces substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the increased net loss, going concern issues, and high operating expenses, despite the strategic shift to a promising service model.

Positives

• Successful sale of the FXR program for $10 million, with potential for up to $50 million in future milestones.
• Received a $5 million milestone payment in July 2026 related to the FXR program.
• Liver toxicology platform achieved 87.5% sensitivity and 100% specificity, described as 'world's best'.
• FDA announcement on April 10, 2025, favoring non-animal New Approach Methodologies (NAM) supports the company's new business model.
• Secured $2.4 million in net proceeds from a public offering on March 31, 2026.

Negatives

• Reported a net loss of $13.8 million for the year ended March 31, 2026, an increase from $2.5 million in the prior year.
• The company has substantial additional funding requirements and faces substantial doubt about its ability to continue as a going concern.
• Operating expenses were $11.6 million for the year ended March 31, 2026, with a significant portion attributed to selling, general, and administrative costs.
• The company's common stock is trading below $1 per share, raising concerns about Nasdaq listing compliance.
• The fair value of common stock warrant liabilities resulted in a $2.7 million loss on issuance in the year ended March 31, 2026.

Risks

• Substantial additional operating losses are expected over the next several years.
• The company's platform technology for developing human tissues and disease models is new and unproven.
• The company may require substantial additional funding, which could cause dilution to existing stockholders.
• Clinical drug development is a lengthy, expensive process with uncertain timelines and outcomes.
• Failure to attract and retain key employees and contractors could adversely impact the business.
• The company faces intense competition in its services and drug discovery efforts.
• The company may not be able to protect its intellectual property rights adequately.
• There is substantial doubt about the company's ability to continue as a going concern.

Future Outlook

VivoSim Labs intends to focus on providing liver and intestinal toxicology insights using NAM models to pharmaceutical and biotech companies. The company anticipates growth in this service area, driven by the FDA's move away from animal testing. However, the company faces significant funding needs and has substantial doubt about its ability to continue as a going concern.

Management Comments

• We believe these attributes can enable critical complex, multicellular disease models that can be used to study and develop clinically effective drugs across multiple therapeutic areas.
• We believe that our existing facilities are adequate to meet our current needs, and that suitable additional alternative spaces will be available in the future on commercially reasonable terms.
• Management has performed an analysis and concluded that substantial doubt exists about our ability to continue as a going concern.

Industry Context

StockSavvy.ai notes that VivoSim Labs' strategic shift aligns with the broader industry trend towards New Approach Methodologies (NAMs) in drug development, driven by regulatory changes and a desire for more predictive, human-relevant testing models. This pivot positions the company to capitalize on the growing demand for in vitro toxicology services.

Comparison to Industry Standards

• VivoSim's liver toxicology platform sensitivity of 87.5% is stated as 'world's best' compared to industry standards, with 100% specificity.
• The company's transition to a services model is a common strategy for biotechnology firms seeking to monetize their platform technology, especially when early-stage drug development proves capital-intensive and high-risk.

Corporate Governance

Legal Proceedings

• H.C. Wainwright & Co., LLC filed a complaint alleging breach of a tail financing provision in an engagement agreement, seeking damages and attorneys fees. VivoSim Labs has filed counterclaims.
• The company is subject to various claims and pending legal actions arising in the normal course of business.

Related Party Transactions

• VivoSim Labs has an intercompany agreement with Viscient Biosciences, Inc., an entity where Executive Chairman Keith Murphy also serves as CEO. Services are exchanged between the companies, and facilities/equipment are shared.
• For fiscal years ended March 31, 2026 and 2025, VivoSim incurred $604,000 and $118,000 respectively in R&D consulting expenses from Viscient.
• Keith Murphy's consulting firm, MDBI, received $800,174 in fiscal 2026 and $726,674 in fiscal 2025 for his services as Executive Chairman.

Stakeholder Impact

• Shareholders may experience dilution due to future equity issuances needed to fund operations.
• The company's going concern status and potential Nasdaq delisting could negatively impact investor confidence and stock liquidity.
• Employees' job security may be affected by the company's financial condition and need for future funding.

Next Steps

• Focus on building the 3D human tissue model services platform.
• Seek additional funding to support future operating activities.
• Continue to develop and refine NAM models for liver and intestinal toxicology.
• Potentially pursue strategic partnerships and collaborations.

Key Dates

Recommendation

While the company's strategic shift to 3D tissue testing services aligns with industry trends and shows promise, the significant net losses, going concern issues, and potential Nasdaq delisting present considerable risks. The company needs to demonstrate a clear path to profitability and secure additional funding to mitigate these concerns. Therefore, a 'hold' recommendation is appropriate, pending further operational and financial improvements.

Keywords

VivoSim Labs, 3D tissue models, drug testing, toxicology, biotechnology, pharmaceutical services, NAM models, Form 10-K